Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RBM25 antisense RNA 1 (RBM25-AS1) is likely a putative noncoding RNA transcript antisense to the coding gene RBM25. There is currently no peer-reviewed literature or database entry that describes its molecular structure, biological function, disease association, or therapeutic relevance. All current knowledge and biomedical research focus on the protein-coding gene RBM25, which encodes an RNA-binding motif protein that regulates alternative splicing of pre-mRNAs, modulates apoptosis, and is implicated in various diseases. No evidence indicates RBM25-AS1 is a recognized or actionable therapeutic target. If you intended information about RBM25 (RNA Binding Motif Protein 25), refer to RBM25 as the canonical target; otherwise, RBM25-AS1 likely refers to an uncharacterized or noncanonical transcript.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RBM25 antisense RNA 1 (RBM25-AS1).